Rabbit Polyclonal LRPAP1 Antibody

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using ANXA1 mouse mAb against Hela (1), A549 (2), K562 (3), NIH3T3 (4), C6 (5), and COS7 (6) cell lysate.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human ovarian cancer tissues using ANXA1 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues using ANXA1 mouse mAb with DAB staining.    

  
  

The LRPAP1 (Low-Density Lipoprotein Receptor-Related Protein Associated Protein 1) antibody targets the LRPAP1 protein, also known as RAP or α-2-MRAP. LRPAP1 is a chaperone protein that interacts with members of the LDL receptor (LDLR) family, including LDLR-related protein 1 (LRP1), to regulate their folding, trafficking, and ligand-binding activity. By binding to these receptors in the endoplasmic reticulum, LRPAP1 prevents premature interaction with ligands and ensures proper conformational maturation. Dysregulation of LRPAP1 has been implicated in diseases linked to LDL receptor family dysfunction, such as Alzheimer’s disease (due to LRP1’s role in amyloid-beta clearance) and atherosclerosis.

LRPAP1 antibodies are essential tools for studying the protein’s expression, localization, and interaction networks in various tissues. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate LRPAP1’s role in cellular processes, including lipid metabolism, cell signaling, and endocytosis. Commercially available antibodies are typically raised in hosts like rabbits or mice, with validation across multiple applications. Research using LRPAP1 antibodies has also explored its potential as a biomarker in cancer, where altered expression correlates with tumor progression and metastasis. Understanding LRPAP1’s molecular mechanisms through antibody-based studies may aid in developing therapeutic strategies targeting receptor-mediated pathways.